SOMNOMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 AUD | 0.00% |
|
+4.17% | -50.00% |
| 13/05 | SomnoMed Pays Loan from Epsilon Direct Lending; Shares Rise 5% | MT |
| 05/05 | SomnoMed Completes AU$16.8 Million Retail Entitlement Offer | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 91.07 | 99.31 | 182.9 | 100.1 | 79.04 | 54.03 | - | - |
| Enterprise Value (EV) 1 | 86.96 | 84.67 | 164.1 | 91.39 | 83.75 | 40.63 | 49.52 | 51 |
| P/E ratio | -5.13 x | -67.8 x | -145 x | -21.4 x | -9.38 x | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.55 x | 1.73 x | 2.92 x | 1.38 x | 0.95 x | 0.61 x | 0.59 x | 0.54 x |
| EV / Revenue | 1.48 x | 1.48 x | 2.62 x | 1.26 x | 1 x | 0.46 x | 0.54 x | 0.51 x |
| EV / EBITDA | 17.6 x | 18 x | 42.1 x | 70.3 x | 39.9 x | -30.1 x | 16.3 x | 8.55 x |
| EV / FCF | -1,10,27,215 x | 2,47,05,884 x | 29,74,61,835 x | 10,75,84,346 x | - | - | - | - |
| FCF Yield | -0% | 0% | 0% | 0% | - | - | - | - |
| Price to Book | 5.11 x | 2.94 x | 5.69 x | 3.6 x | 3.53 x | 1.11 x | 1.17 x | 1.16 x |
| Nbr of stocks (in thousands) | 62,804 | 82,759 | 82,759 | 82,759 | 82,759 | 2,16,108 | - | - |
| Reference price 2 | 1.450 | 1.200 | 2.210 | 1.210 | 0.9550 | 0.2500 | 0.2500 | 0.2500 |
| Announcement Date | 20/08/19 | 23/08/20 | 23/08/21 | 22/08/22 | 30/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 58.89 | 57.3 | 62.71 | 72.58 | 83.62 | 88.63 | 91.6 | 100.1 |
| EBITDA 1 | 4.945 | 4.7 | 3.9 | 1.3 | 2.1 | -1.348 | 3.034 | 5.968 |
| EBIT 1 | 3.496 | -0.5252 | -0.618 | -2.941 | -4.073 | -6.979 | -2.991 | -0.0322 |
| Operating Margin | 5.94% | -0.92% | -0.99% | -4.05% | -4.87% | -7.87% | -3.27% | -0.03% |
| Earnings before Tax (EBT) | 0.6072 | 0.747 | -0.7339 | -3.496 | -7.045 | - | - | - |
| Net income | -16.44 | -1.119 | -1.193 | -4.437 | -7.999 | - | - | - |
| Net margin | -27.91% | -1.95% | -1.9% | -6.11% | -9.57% | - | - | - |
| EPS | -0.2828 | -0.0177 | -0.0152 | -0.0565 | -0.1018 | - | - | - |
| Free Cash Flow | -7.886 | 3.427 | 0.5518 | 0.8494 | - | - | - | - |
| FCF margin | -13.39% | 5.98% | 0.88% | 1.17% | - | - | - | - |
| FCF Conversion (EBITDA) | - | 72.91% | 14.15% | 65.34% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20/08/19 | 23/08/20 | 23/08/21 | 22/08/22 | 30/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2021 S1 | 2021 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 33.26 | 30.82 | 31.88 | - | 43.66 |
| EBITDA 1 | 3.008 | - | 0.7 | - | 1.3 |
| EBIT 1 | 1.452 | - | -1.533 | - | -1.997 |
| Operating Margin | 4.37% | - | -4.81% | - | -4.57% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | -3.745 | - |
| Net margin | - | - | - | - | - |
| EPS | 0.0123 | 0.005900 | - | -0.0477 | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 17/02/20 | 22/02/21 | 23/08/21 | 22/02/23 | 30/08/23 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 4.71 | - | - | - |
| Net Cash position 1 | 4.1 | 14.6 | 18.8 | 8.75 | - | 13.4 | 4.51 | 3.03 |
| Leverage (Debt/EBITDA) | - | - | - | - | 2.244 x | - | - | - |
| Free Cash Flow | -7.89 | 3.43 | 0.55 | 0.85 | - | - | - | - |
| ROE (net income / shareholders' equity) | 7.42% | -4.33% | -3.62% | -14.8% | -31.3% | - | - | - |
| ROA (Net income/ Total Assets) | -40.9% | -2.31% | -2.02% | -7.77% | -13% | - | - | - |
| Assets | 40.22 | 48.42 | 58.93 | 57.13 | 61.31 | - | - | - |
| Book Value Per Share 2 | 0.2800 | 0.4100 | 0.3900 | 0.3400 | 0.2700 | 0.2300 | 0.2100 | 0.2200 |
| Cash Flow per Share 2 | -0.1000 | 0.0800 | 0.0300 | 0.0200 | -0.0500 | -0.0500 | -0.0100 | 0.0200 |
| Capex 1 | 1.34 | 1.76 | 2.15 | 1.01 | 6.4 | 4.96 | 6.03 | 6 |
| Capex / Sales | 2.27% | 3.08% | 3.44% | 1.39% | 7.65% | 5.59% | 6.58% | 5.99% |
| Announcement Date | 20/08/19 | 23/08/20 | 23/08/21 | 22/08/22 | 30/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.25
AUD
Average target price
0.23
AUD
Spread / Average Target
-8.00%
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 3.59Cr | |
| -4.72% | 18TCr | |
| -2.83% | 10TCr | |
| -5.01% | 6.69TCr | |
| +15.53% | 4.67TCr | |
| -8.53% | 4.51TCr | |
| +5.82% | 4.16TCr | |
| +17.67% | 3.05TCr | |
| +14.00% | 2.43TCr | |
| -8.08% | 2.36TCr |
- Stock Market
- Equities
- SOM Stock
- Financials SomnoMed Limited
